Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 13/20 | 0.65 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 2/20 | 0.39 |
| ▸ | NOS3 | P29474 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
| ▸ | NOS2 | P35228 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2542798 | 1.00 | METAP2 (0.65) | METAP2FFAR2FAAHNOS3NOS1 | |
| SCHEMBL12233044 | 0.90 | METAP2 (0.66) | METAP2FFAR2FAAHNOS3NOS1 | |
| SCHEMBL7980098 | 0.89 | METAP2 (0.65) | METAP2FFAR2FAAHNOS3NOS1 | |
| SCHEMBL2544578 | 0.85 | METAP2 (0.73) | METAP2FFAR2FAAHNOS3NOS1 | |
| SCHEMBL1396808 | 0.85 | METAP2 (0.73) | METAP2FFAR2FAAHNOS3NOS1 | |
| SCHEMBL2539728 | 0.82 | METAP2 (0.61) | METAP2FFAR2FAAHNOS3NOS1 | |
| SCHEMBL2539733 | 0.82 | METAP2 (0.61) | METAP2FFAR2FAAHNOS3NOS1 | |
| SCHEMBL2548665 | 0.79 | METAP2 (0.71) | METAP2FAAH | |
| SCHEMBL2548670 | 0.79 | METAP2 (0.71) | METAP2FAAH | |
| SCHEMBL14984950 | 0.78 | METAP2 (0.51) | METAP2FFAR2NOS3NOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2288351-B1 | NOVEL PYRROLIDONE DERIVATIVES FOR USE AS METAP-2 INHIBITORS | MERCK PATENT GMBH (DE) | 2018-08-08 | — | — | EP | claimed |
| US-8846694-B2 | Pyrrolidone derivatives for use as MetAP-2 inhibitors | MERCK PATENT GMBH (DE) | 2014-09-30 | — | — | US | claimed |
| US-20110263561-A1 | Novel pyrrolidone derivatives for use as MetAP-2 inhibitors | MERCK PATENT GMBH (DE) | 2011-10-27 | — | — | US | claimed |
| US-8846694-B2 | Pyrrolidone derivatives for use as MetAP-2 inhibitors | MERCK PATENT GMBH (DE) | 2014-09-30 | — | — | US | disclosed |
| US-20110263561-A1 | Novel pyrrolidone derivatives for use as MetAP-2 inhibitors | MERCK PATENT GMBH (DE) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263561-A1 | Novel pyrrolidone derivatives for use as MetAP-2 inhibitors | METAP2, METAP1, ENPEP | METAP2 1/4885FFAR2 3574/4885FAAH 2378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.